Oxigene faces challenges for ovarian cancer drug
Detailed results from Oxigene's phase II study of fosbretabulin plus Avastin in recurrent ovarian cancer were presented this week. The combination of the two drugs reduced the risk of tumor progression in patients with recurrent ovarian cancer.